Bryn Mawr Trust Advisors LLC Trims Stake in Zimmer Biomet Holdings, Inc. $ZBH

Bryn Mawr Trust Advisors LLC lowered its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 39.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 39,824 shares of the medical equipment provider’s stock after selling 25,448 shares during the quarter. Bryn Mawr Trust Advisors LLC’s holdings in Zimmer Biomet were worth $3,581,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in ZBH. Key Financial Inc raised its stake in shares of Zimmer Biomet by 164.6% in the third quarter. Key Financial Inc now owns 262 shares of the medical equipment provider’s stock valued at $26,000 after acquiring an additional 163 shares during the period. Cullen Frost Bankers Inc. raised its stake in shares of Zimmer Biomet by 66.7% in the third quarter. Cullen Frost Bankers Inc. now owns 290 shares of the medical equipment provider’s stock valued at $29,000 after acquiring an additional 116 shares during the period. Root Financial Partners LLC purchased a new stake in shares of Zimmer Biomet in the third quarter valued at $31,000. Flagship Harbor Advisors LLC purchased a new position in Zimmer Biomet in the 4th quarter worth about $32,000. Finally, Grove Bank & Trust increased its stake in Zimmer Biomet by 431.6% in the 4th quarter. Grove Bank & Trust now owns 404 shares of the medical equipment provider’s stock worth $36,000 after buying an additional 328 shares during the period. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Trading Down 1.4%

ZBH stock opened at $82.24 on Friday. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.73 and a quick ratio of 0.95. Zimmer Biomet Holdings, Inc. has a 12 month low of $79.83 and a 12 month high of $108.29. The firm’s 50-day moving average is $91.56 and its 200 day moving average is $92.31. The company has a market capitalization of $15.91 billion, a PE ratio of 21.36, a P/E/G ratio of 1.90 and a beta of 0.48.

Zimmer Biomet (NYSE:ZBH) last issued its earnings results on Tuesday, April 28th. The medical equipment provider reported $2.09 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.86 by $0.23. Zimmer Biomet had a net margin of 9.05% and a return on equity of 13.24%. The company had revenue of $2.09 billion for the quarter, compared to analysts’ expectations of $2.07 billion. During the same period in the prior year, the business earned $1.81 EPS. The firm’s quarterly revenue was up 9.3% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. On average, research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.47 EPS for the current year.

Zimmer Biomet Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, April 30th. Shareholders of record on Tuesday, March 31st were issued a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 1.2%. The ex-dividend date was Tuesday, March 31st. Zimmer Biomet’s dividend payout ratio is presently 24.94%.

Insider Transactions at Zimmer Biomet

In other Zimmer Biomet news, SVP Lori Winkler sold 2,650 shares of the stock in a transaction dated Thursday, March 12th. The shares were sold at an average price of $94.66, for a total transaction of $250,849.00. Following the transaction, the senior vice president directly owned 10,224 shares in the company, valued at $967,803.84. This represents a 20.58% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 1.28% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several research firms recently commented on ZBH. JPMorgan Chase & Co. reduced their price target on shares of Zimmer Biomet from $100.00 to $95.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 29th. Wells Fargo & Company reduced their price target on shares of Zimmer Biomet from $98.00 to $90.00 and set an “equal weight” rating on the stock in a research note on Wednesday, April 29th. Leerink Partners began coverage on shares of Zimmer Biomet in a research note on Monday, April 13th. They issued a “hold” rating and a $101.00 price target on the stock. Truist Financial reaffirmed a “hold” rating and issued a $92.00 price target (down from $98.00) on shares of Zimmer Biomet in a research note on Wednesday, April 29th. Finally, William Blair began coverage on shares of Zimmer Biomet in a research note on Friday, February 20th. They issued a “market perform” rating on the stock. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, twelve have given a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $102.80.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.